Business Wire

PA-PCI-PHARMA-SERVICES

Share
PCI Pharma Services Announces Global Expansion of Clinical Trial Services

PCI Pharma Services (PCI) , a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, today announced a significant milestone in its global clinical footprint with the creation of a new Clinical Center of Excellence (COE) in Western Europe at its Berlin location, a major investment that will represent a new flagship site for customers. This is part of PCI’s global strategy to expand its clinical supply-chain network into continental Europe to complement offerings available at its UK and Ireland sites. The COE is expected to be completed in January 2021.

“With this expansion, our Berlin Clinical Center of Excellence will address the needs of European and global clients,” said Brian Keesee, vice president and general manager, Global Clinical Operations and Supply, PCI Pharma Services. “Berlin is an excellent logistical hub that will serve as a proactive solution to Brexit, ensuring there are no gaps in the supply chain and our clients conducting clinical trials in all parts of Europe continue to be served.”

The Berlin COE will include 17,000 square feet of space dedicated to primary and secondary packaging, storage of pharmaceutical and biopharmaceutical therapies at all temperature ranges, and distribution. This capacity is well positioned to service the EU-based clinical trials ecosystem, which currently has more than 38,100 active trials sites throughout the 27-member countries and is second only to the United States for such research. Of the EU countries, France and Germany rank first and second, with 7,370 and 4,418 active trial sites, respectively.i

“Our strategy has always been to increase the capacity and capabilities of our clinical trial services network, and with the acquisition of Bellwyck Pharma Services earlier this year, we are taking the next step to enhance our capabilities at our new Berlin facility to support the growing clinical trial market in Europe and beyond,” said Salim Haffar, chief executive officer, PCI Pharma Services. “This investment will provide clients with global clinical trial solutions for their life-changing medicines, ensuring continuity of patient supply to match growing market demands.”

About PCI Pharma Services

The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enable us to address global development needs throughout the product life cycle — from Phase I Clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pci.com or follow us on Twitter at @PCI_Social.

___________________
i ClinicalTrials.gov Web site. Advanced Search of Trial Status Active, not recruiting; Recruiting; Enrolling by invitation. Bethesda (MD): National Library of Medicine (US). Available: https://clinicaltrials.gov/ct2/results/map?recrs=adf&map= . Accessed 2020 July 27.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rimini Street Announces Upcoming 2025 Investor Conference Schedule15.5.2025 22:51:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced that Michael L. Perica, chief financial officer, and Dean Pohl, vice president, treasurer and investor relations, will be presenting and meeting with investors one-on-one and in small group meetings at the following conferences: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515374696/en/ Rimini Street Announces Upcoming 2025 Investor Conference Schedule May 28, 2025: Craig-Hallum 22nd Annual Institutional Investor Conference, Minneapolis May 29, 2025: TD Cowen 53rd Annual TMT Conference, New York City Fireside Chat: 1:15 pm Eastern, webcast link June 24-26, 2025: Roth 15th Annual London Conference, London To schedule a meeting please contact your salesperson or Rimini Street Investor Relations at IR@rimin

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States15.5.2025 20:30:00 CEST | Press release

Zynyz® (retifanlimab-dlwr), a PD-1 inhibitor, is now approved for the treatment of advanced squamous cell carcinoma of the anal canal (SCAC) in combination with chemotherapy and as a monotherapyPatients with SCAC treated with Zynyz achieved a statistically significant improvement in progression-free survival and improvement in overall survival Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz® (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). In addition, the FDA granted approval for Zynyz as a single agent for the treatment of adult patients with locally recurrent or with metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy. Thi

DDC Announces Record 2024 Growth and Strategic Bitcoin Reserve Initiative in Shareholder Letter by Founder & CEO Norma Chu15.5.2025 20:23:00 CEST | Press release

DDC Enterprise Ltd. (NYSEAM: DDC), today released its 2024 full year results alongside a Shareholder Letter from Founder, Chairwoman, and CEO Norma Chu, underscoring the company’s positive financial performance and unveiling a pioneering Bitcoin accumulation strategy poised to redefine long-term value creation. To Our Valued Shareholders, 2024 was a year of transformative growth and strategic milestones for DDC. I am thrilled to share that we not only met our financial forecasts but exceeded expectations, delivering strong performance across key metrics while laying the groundwork for an even more exciting future. As we enter 2025, our momentum is accelerating, driven by disciplined execution and a bold new chapter in our corporate strategy. 2024 Financial & Operational HighlightsRevenue Growth: USD 37.4 million, a 33% year-over-year increase, propelled by the strategic acquisition of U.S. brands and sustained resilience in our core China operations. Margin Expansion: Gross profit marg

Ras Al Khaimah’s Strong Economic and Investment Environment Validated by Fitch Affirmation of ‘A+’ Credit Rating, With Stable Outlook15.5.2025 20:18:00 CEST | Press release

The positive rating reflects the Emirate’s strong long-term growth prospects and ongoing economic diversification Ras Al Khaimah’s strategic approach to sustainable, cross-sector growth and strong economic and investment environment has been validated by international credit rating agency Fitch, which reaffirmed the rating at ‘A+’ with a stable outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515907689/en/ Ras Al Khaimah’s strong economic and investment environment validated by Fitch affirmation of ‘A+’ credit rating, with Stable Outlook (Photo: AETOSWire) Ras Al Khaimah Government welcomed the announcement as an endorsement of the Emirate’s resilient and expanding economy, sound fiscal management and the clear vision and unwavering commitment of its leadership to sustainable, long-term development and growth. The Emirate’s landmark tourism projects, including a major integrated resort, luxury hotels and world-clas

Cessna Citation CJ4 Gen3 Flight Test Program Advances Through Milestones as Second Test Article Takes Flight15.5.2025 20:00:00 CEST | Press release

Textron Aviation today announced a major program milestone for the Cessna Citation CJ4 Gen3 flight test program with the successful first flight of a second test article — P1. Testing on the P1 aircraft will focus on avionics, human factors and interiors. The Citation CJ4 Gen3 business jet is designed to keep pilots a step ahead in the cockpit by offering the next-generation Garmin G3000 PRIME avionics along with the most standard features in its class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515438856/en/ Cessna Citation CJ4 Gen3 flight test program advances through milestones as second test article takes flight. (Photo Credit: Textron Aviation) The Cessna Citation CJ4 Gen3 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. “This achievement continues the forward momentum of the CJ4 Gen3 program and reflects the dedication and expertise of our team in designing, certifying an

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye